Mainz Biomed Reports Topline Results From Pooled Study Evaluating Novel MRNA Biomarkers And Proprietary AI Algorithm For Integration Into Pivotal FDA PMA Clinical Trial For Next Generation Colorectal Cancer Diagnostic

Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82%690 subjects analyzed including pr

BenzingaApr 25 09:30 ET

Mainz Biomed Secures New Funding Agreement

TipRanksApr 19 07:29 ET

Express News | Cantor Fitzgerald Reiterates Neutral on Mainz Biomed

Moomoo 24/7Apr 12 09:58 ET

Analysts' Top Healthcare Picks: Mainz Biomed B.V. (MYNZ), Century Therapeutics (IPSC)

TipRanksApr 12 06:20 ET

Express News | Mainz Biomed NV : H.c. Wainwright Cuts Target Price to $2 From $3

Moomoo 24/7Apr 12 06:08 ET

Mainz Biomed 2023 Rev $895,500 >MYNZ

Mainz Biomed 2023 Rev $895,500 >MYNZ

Dow JonesApr 9 08:03 ET